Clinical practice guidelines: Standards, options and recommendations for first line medical treatment of patients with ovarian neoplasms (summary report);Recommandations pour la pratique clinique: Standards, options et recommandations 2003 pour le traitement médical de première ligne des patientes atteintes de tumeurs épithéliales malignes de l'ovaire, mise à jour (rapport abrégé)

Bulletin du Cancer

Volumn 91, Issue 7-8, 2004, Pages 609-620

  Lhommé, Catherine ^a   Ray Coquard, Isabelle ^b   Guastalla, Jean Pierre ^b   Bataillard, Anne ^c   Thomas, Laurence ^d   Bonnier, Pascal ^e   Dargent, Daniel ^f   Dohollou, Nicole ^g   Ganem, Gérard ^h   Lefranc, Jean Pierre ⁱ   Misset, Jean Louis ^j   Rixe, Olivier ⁱ   Tchiknavorian, Xavier ^k   Tournigand, Christophe ^l   Villet, Richard ^m   Bachelot, Thomas ^b   Kerbrat, Pierre ⁿ   Fervers, Béatrice ^c   Basuyau, Jean Pierre ^o   Cohen Solal Le Nir, Christine ^p   Morice, Philippe ^a   Duvillard, Pierre ^a   Voog, Éric ^q   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE LÉON BÉRARD   (France)

^c FNCLCC   (France)

^d INSTITUT BERGONIÉ   (France)

^e HÔPITAL DE LA CONCEPTION   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g Polyclinique Bordeaux Nord Aquitaine ^*  (France)

^h CENTRE JEAN BERNARD   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j SAINT LOUIS HOSPITAL   (France)

^k Centre Hospitalier Intercommunal   (France)

^l HÔPITAL SAINT ANTOINE   (France)

^m Hopital des Diaconesses   (France)

ⁿ CENTRE EUGÈNE MARQUIS   (France)

^o CENTRE HENRI BECQUEREL   (France)

^p CENTRE RENÉ HUGUENIN   (France)

^q Clinique Victor Hugo   (France)

more..

Author keywords

Adult; Chemotherapy; Clinical practice guidelines; Ovarian neoplasm; Taxanes

Indexed keywords

CARBOPLATIN; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ALGORITHM; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; GYNECOLOGY; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; ONCOLOGY; OVARY CANCER; PRACTICE GUIDELINE; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BCG VACCINE; DECISION TREES; FEMALE; HUMANS; OVARIAN NEOPLASMS; TAMOXIFEN;

EID: 4344639447     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Fervers B, Bonichon F, Demard F, Heron JF, Mathoulin S, Philip T, et al. Méthodologie de développement des Standards, Options et Recommandations diagnostiques et thérapeutiques en cancérologie. Bull Cancer 1995 ; 82 : 761-7.
2. Fervers B, Hardy J, Blanc-Vincent MP, Theobald S, Bataillard A, Farsi F, et al. SOR : project methodology. Br J Cancer 2001 (Suppl 2) ; 84 : 8-16.
3. Fanning J, Bennett TZ, Hilgers RD. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 1992 ; 80 : 954-60.
4. West RJ, Zweig SF. Meta-analysis of chemotherapy regimens for ovarian carcinoma : a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide. Eur J Gyraecol Oncol 1997 ; 18 : 343-8.
5. McGuire WP, Hoskins WJ, Brady M, et al. Long-term follow-up of GOG-111 : a randomized trial comparing cisplatin combined with cyclophosphamide or paclitaxel in patients with stages III or IV epithelial ovarian cancer. Int J Gynecol Cancer 1999 ; 9 : 8.
6. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxe. versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer : three-year results. J Nat Cancer Inst 2000 ; 92 : 699-708.
7. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclicxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer : A Gynecologic Oncology Group study. J Clin Oncol 2000 ; 18 : 106-15.
8. ICON3. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer : the ICON3 rindomised trial. Lancet 2002 ; 360 : 505-15.
9. Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, et al. International Collaborative Ovarian Neoplasm trial 1 : a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancet. J Natl Cancer Inst 2003 ; 95 : 125-32.
10. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma : European Organisation fot Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003 ; 95 : 113-25.
11. Kojs Z, Glinski B, Reinfuss M, Pudelek J, Urbanski K, Kowalska T, et al. Résultats d'un essai prospectif randomisé comparant une radiothérapie abdominopelvienne postopératoire et une chimiothérapie postopératoire dans les cancers de l'ovaire précoces. Radiotherapy versus chemotherapy in postoperative treatment of early ovarian cancer. Results of a randomized trial. Cancer/Radiotherapie 2001 ; 5 : 5-11.